Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In-Jin Jang

Showing results (131-140 of 292) with videos related to

Pageof 30
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 29, 2017
LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male SubjectsHeechan Lee, Hyewon Chung, SeungHwan Lee, et al.
Chinese Clinical Oncology|July 18, 2019
Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, KoreaSeock-Ah Im, Dae-Won Lee, Ryungwoo Kang, et al.
Scientific Reports|January 31, 2015
Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathwayKumsun Cho, Jae Yong Chung, Sung Kweon Cho, et al.
Clinical and Translational Science|September 30, 2022
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first-in-class, first-in-human studyJoo Young Na, Deok Yong Yoon, Hyounggyoon Yoo, et al.
Drug Metabolism and Pharmacokinetics|May 16, 2019
Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducersJieon Lee, Seo Hyun Yoon, Sojeong Yi, et al.
Clinical Therapeutics|September 4, 2017
Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male SubjectsYun Kim, Anhye Kim, SeungHwan Lee, et al.
Therapeutic Drug Monitoring|July 18, 2024
Coadministration of Voriconazole and Rifabutin Can Increase the Risk of Adverse Drug Reactions in Patients With Multiple InfectionsYoonjin Kim, Sungyeun Bae, Ki Young Huh, et al.
Clinical Therapeutics|January 31, 2012
Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studiesTae-Eun Kim, Namyi Gu, Seo Hyun Yoon, et al.
Journal of Clinical Pharmacology|March 9, 2011
Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteersSeungHwan Lee, Bo-Hyung Kim, Won-Seok Nam, et al.
Therapeutic Drug Monitoring|July 16, 2013
GC-MS-based quantitative signatures of cytochrome P450-mediated steroid oxidation induced by rifampicinJu-Yeon Moon, Se Mi Kang, Jeongae Lee, et al.
Pageof 30

Showing results (131-140 of 292) with videos related to

Sort By:
Pageof 30
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 29, 2017
LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male SubjectsHeechan Lee, Hyewon Chung, SeungHwan Lee, et al.
Chinese Clinical Oncology|July 18, 2019
Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, KoreaSeock-Ah Im, Dae-Won Lee, Ryungwoo Kang, et al.
Scientific Reports|January 31, 2015
Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathwayKumsun Cho, Jae Yong Chung, Sung Kweon Cho, et al.
Clinical and Translational Science|September 30, 2022
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first-in-class, first-in-human studyJoo Young Na, Deok Yong Yoon, Hyounggyoon Yoo, et al.
Drug Metabolism and Pharmacokinetics|May 16, 2019
Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducersJieon Lee, Seo Hyun Yoon, Sojeong Yi, et al.
Clinical Therapeutics|September 4, 2017
Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male SubjectsYun Kim, Anhye Kim, SeungHwan Lee, et al.
Therapeutic Drug Monitoring|July 18, 2024
Coadministration of Voriconazole and Rifabutin Can Increase the Risk of Adverse Drug Reactions in Patients With Multiple InfectionsYoonjin Kim, Sungyeun Bae, Ki Young Huh, et al.
Clinical Therapeutics|January 31, 2012
Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studiesTae-Eun Kim, Namyi Gu, Seo Hyun Yoon, et al.
Journal of Clinical Pharmacology|March 9, 2011
Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteersSeungHwan Lee, Bo-Hyung Kim, Won-Seok Nam, et al.
Therapeutic Drug Monitoring|July 16, 2013
GC-MS-based quantitative signatures of cytochrome P450-mediated steroid oxidation induced by rifampicinJu-Yeon Moon, Se Mi Kang, Jeongae Lee, et al.
Pageof 30